Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medical Imaging
  4. Fast Track Articles
  5. Fast Track Article
image of Correlation between Liver fat Content Determined by Ultrasonic Attenuation Imaging and Lipid Metabolism in Patients with Non-Alcoholic Fatty Liver Disease
file format pdf download PDF

Abstract

Objective:

This study aimed to investigate the utility of ultrasonic attenuation imaging (ATI) in assessing the relationship between hepatic fat content and lipid metabolism in patients diagnosed with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD).

Methods:

239 patients diagnosed with T2DM were included, with liver fat quantified using proton density fat fraction (PDFF). We analyzed the variance in ATI across various grades of fatty liver and its correlation with clinical parameters. Additionally, a receiver operating characteristic curve (ROC) was employed to evaluate the diagnostic accuracy of ATI for different degrees of fatty liver, determining optimal diagnostic thresholds while calculating sensitivity and specificity. Furthermore, we assessed the reliability of ATI and SWE in measuring liver acoustic attenuation and elastic stiffness using the intraclass correlation coefficient (ICC).

Results:

We observed significant variations in ATI across different grades of fatty liver (<0.001). ATI exhibited positive correlations with SWE, BMI, GLU (OH), steatosis grade, ALT, TG, and UA, while demonstrating a negative correlation with HDL-c. Notably, the correlation coefficient with steatosis grade was 0.76, indicating a strong association. The equation for the stepwise multiple linear regression model used is as follows: ATI=0.338+0.014×TG+0.052×BMI+0.001×ALT+0.113×SWE. AUROCs indicated the best cutoffs for ATI in different degrees of steatosis to be as follows: ≥ S1 = 0.665 dB·cm-1·MHz-1 (AUC = 0.857); ≥ S2 = 0.705 dB·cm-1·MHz-1 (AUC = 0.921); ≥ S3 = 0.745 dB·cm-1·MHz-1 (AUC = 0.935). The ICC values for ATI and SWE in liver-mimicking measurements exceeded 0.75 (<0.001), signifying excellent repeatability.

Conclusion:

The ATI could quantitatively assess the severity of fatty liver, enabling effective identification of patients suitable for liver biopsy referral.

2025 © 2025 The Author(s). Published by Bentham Science Publisher. The Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056335310250217064323
2025-03-17
2025-04-02

  • From This Site

    /content/journals/cmir/10.2174/0115734056335310250217064323
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. Wong W.K. Chan W.K. Nonalcoholic fatty liver disease: A global perspective. Clin. Ther. 2021 43 3 473 499 10.1016/j.clinthera.2021.01.007 33526312
    [Google Scholar]
  2. Targher G. Corey K.E. Byrne C.D. Roden M. The complex link between NAFLD and type 2 diabetes mellitus — Mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. 2021 18 9 599 612 10.1038/s41575‑021‑00448‑y 33972770
    [Google Scholar]
  3. Lee Y.S. Yoo Y.J. Jung Y.K. Kim J.H. Seo Y.S. Yim H.J. Kim I.H. Lee S.Y. Kim B.H. Kim J.W. Lee C.H. Yeon J.E. Kwon S.Y. Um S.H. Byun K.S. Multiparametric MR is a valuable modality for evaluating disease severity of nonalcoholic fatty liver disease. Clin. Transl. Gastroenterol. 2020 11 4 e00157 10.14309/ctg.0000000000000157 32251018
    [Google Scholar]
  4. Ferguson D. Finck B.N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2021 17 8 484 495 10.1038/s41574‑021‑00507‑z 34131333
    [Google Scholar]
  5. Kleiner D.E. Brunt E.M. Wilson L.A. Behling C. Guy C. Contos M. Cummings O. Yeh M. Gill R. Chalasani N. Neuschwander-Tetri B.A. Diehl A.M. Dasarathy S. Terrault N. Kowdley K. Loomba R. Belt P. Tonascia J. Lavine J.E. Sanyal A.J. Nonalcoholic Steatohepatitis Clinical Research Network Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. Open 2019 2 10 e1912565 10.1001/jamanetworkopen.2019.12565 31584681
    [Google Scholar]
  6. Tokushige K. Ikejima K. Ono M. Eguchi Y. Kamada Y. Itoh Y. Akuta N. Yoneda M. Iwasa M. Yoneda M. Otsuka M. Tamaki N. Kogiso T. Miwa H. Chayama K. Enomoto N. Shimosegawa T. Takehara T. Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J. Gastroenterol. 2021 56 11 951 963 10.1007/s00535‑021‑01796‑x 34533632
    [Google Scholar]
  7. Powell E.E. Wong V.W.S. Rinella M. Non-alcoholic fatty liver disease. Lancet 2021 397 10290 2212 2224 10.1016/S0140‑6736(20)32511‑3 33894145
    [Google Scholar]
  8. Khan R.S. Newsome P.N. Fat and fibrosis: Does empagliflozin impair the progression of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus? Dig. Dis. Sci. 2020 65 2 342 344 10.1007/s10620‑019‑05573‑y 30847693
    [Google Scholar]
  9. Ginès P. Krag A. Abraldes J.G. Solà E. Fabrellas N. Kamath P.S. Liver cirrhosis. Lancet 2021 398 10308 1359 1376 10.1016/S0140‑6736(21)01374‑X 34543610
    [Google Scholar]
  10. Yoshizawa E Yamada A. MRI-derived proton density fat fraction. J Med Ultrason (2001) 2021 48 4 497 506 10.1007/s10396‑021‑01135‑w
    [Google Scholar]
  11. Tamaki N. Ajmera V. Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat. Rev. Endocrinol. 2022 18 1 55 66 10.1038/s41574‑021‑00584‑0 34815553
    [Google Scholar]
  12. Newsome P.N. Sasso M. Deeks J.J. Paredes A. Boursier J. Chan W.K. Yilmaz Y. Czernichow S. Zheng M.H. Wong V.W.S. Allison M. Tsochatzis E. Anstee Q.M. Sheridan D.A. Eddowes P.J. Guha I.N. Cobbold J.F. Paradis V. Bedossa P. Miette V. Fournier-Poizat C. Sandrin L. Harrison S.A. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 2020 5 4 362 373 10.1016/S2468‑1253(19)30383‑8 32027858
    [Google Scholar]
  13. Chalasani N. Younossi Z. Lavine J.E. Charlton M. Cusi K. Rinella M. Harrison S.A. Brunt E.M. Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 2018 67 1 328 357 10.1002/hep.29367 28714183
    [Google Scholar]
  14. Heinitz S. Müller J. Jenderka K.V. Schlögl H. Stumvoll M. Blüher M. Blank V. Karlas T. The application of high-performance ultrasound probes increases anatomic depiction in obese patients. Sci. Rep. 2023 13 1 16297 10.1038/s41598‑023‑43509‑9 37770538
    [Google Scholar]
  15. Kimura S. Tanaka K. Oeda S. Inoue K. Inadomi C. Kubotsu Y. Yoshioka W. Okada M. Isoda H. Kuwashiro T. Akiyama T. Kurashige A. Oshima A. Oshima M. Matsumoto Y. Kawaguchi A. Anzai K. Sueoka E. Aishima S. Takahashi H. Effect of skin–capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease. Sci. Rep. 2021 11 1 15641 10.1038/s41598‑021‑94970‑3 34341368
    [Google Scholar]
  16. Shao C. Ye J. Dong Z. Li F. Lin Y. Liao B. Feng S. Zhong B. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease. Ther. Adv. Chronic Dis. 2021 12 20406223211033119 10.1177/20406223211033119 34408822
    [Google Scholar]
  17. Francque S M Marchesini G Kautz A Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021 3 5 100322 10.1016/j.jhepr.2021.100322
    [Google Scholar]
  18. Lomonaco R. Godinez Leiva E. Bril F. Shrestha S. Mansour L. Budd J. Portillo Romero J. Schmidt S. Chang K.L. Samraj G. Malaty J. Huber K. Bedossa P. Kalavalapalli S. Marte J. Barb D. Poulton D. Fanous N. Cusi K. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: The need for systematic screening. Diabetes Care 2021 44 2 399 406 10.2337/dc20‑1997 33355256
    [Google Scholar]
  19. Drożdż K. Nabrdalik K. Hajzler W. Kwiendacz H. Gumprecht J. Lip G.Y.H. Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: Associations with fructose metabolism and gut microbiota. Nutrients 2021 14 1 103 10.3390/nu14010103 35010976
    [Google Scholar]
  20. Mantovani A. Petracca G. Beatrice G. Tilg H. Byrne C.D. Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals. Gut 2021 70 5 962 969 10.1136/gutjnl‑2020‑322572 32938692
    [Google Scholar]
  21. Ajmera V. Cepin S. Tesfai K. Hofflich H. Cadman K. Lopez S. Madamba E. Bettencourt R. Richards L. Behling C. Sirlin C.B. Loomba R. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 2023 78 3 471 478 10.1016/j.jhep.2022.11.010 36410554
    [Google Scholar]
  22. Simon T.G. Roelstraete B. Sharma R. Khalili H. Hagström H. Ludvigsson J.F. Cancer risk in patients with biopsy‐confirmed nonalcoholic fatty liver disease: A population‐based cohort study. Hepatology 2021 74 5 2410 2423 10.1002/hep.31845 33811766
    [Google Scholar]
  23. Jang J.K. Kim S.Y. Yoo I.W. Cho Y.B. Kang H.J. Lee D.H. Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis. Eur. Radiol. 2022 32 3 2070 2077 10.1007/s00330‑021‑08269‑y 34549325
    [Google Scholar]
  24. Ferraioli G. Maiocchi L. Raciti M.V. Tinelli C. De Silvestri A. Nichetti M. De Cata P. Rondanelli M. Chiovato L. Calliada F. Filice C. Detection of liver steatosis with a novel ultrasound-based technique: A pilot study using MRI-derived proton density fat fraction as the gold standard. Clin. Transl. Gastroenterol. 2019 10 10 e00081 10.14309/ctg.0000000000000081 31609745
    [Google Scholar]
  25. Gu J. Liu S. Du S. Zhang Q. Xiao J. Dong Q. Xin Y. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis. Eur. Radiol. 2019 29 7 3564 3573 10.1007/s00330‑019‑06072‑4 30899974
    [Google Scholar]
  26. Fowler K.J. Venkatesh S.K. Obuchowski N. Middleton M.S. Chen J. Pepin K. Magnuson J. Brown K.J. Batakis D. Henderson W.C. Shankar S.S. Kamphaus T.N. Pasek A. Calle R.A. Sanyal A.J. Loomba R. Ehman R. Samir A.E. Sirlin C.B. Sherlock S.P. Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: The NIMBLE consortium. Radiology 2023 309 1 e231092 10.1148/radiol.231092 37815451
    [Google Scholar]
  27. Lin H. Lee H.W. Yip T.C.F. Tsochatzis E. Petta S. Bugianesi E. Yoneda M. Zheng M.H. Hagström H. Boursier J. Calleja J.L. Goh G.B.B. Chan W.K. Gallego-Durán R. Sanyal A.J. de Lédinghen V. Newsome P.N. Fan J.G. Castéra L. Lai M. Harrison S.A. Fournier-Poizat C. Wong G.L.H. Pennisi G. Armandi A. Nakajima A. Liu W.Y. Shang Y. de Saint-Loup M. Llop E. Teh K.K.J. Lara-Romero C. Asgharpour A. Mahgoub S. Chan M.S.W. Canivet C.M. Romero-Gomez M. Kim S.U. Wong V.W.S. VCTE-Prognosis Study Group Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA 2024 331 15 1287 1297 10.1001/jama.2024.1447 38512249
    [Google Scholar]
  28. Sanyal A.J. Foucquier J. Younossi Z.M. Harrison S.A. Newsome P.N. Chan W.K. Yilmaz Y. De Ledinghen V. Costentin C. Zheng M.H. Wai-Sun Wong V. Elkhashab M. Huss R.S. Myers R.P. Roux M. Labourdette A. Destro M. Fournier-Poizat C. Miette V. Sandrin L. Boursier J. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using fibroscan-based agile scores. J. Hepatol. 2023 78 2 247 259 10.1016/j.jhep.2022.10.034 36375686
    [Google Scholar]
  29. Eddowes P.J. Sasso M. Allison M. Tsochatzis E. Anstee Q.M. Sheridan D. Guha I.N. Cobbold J.F. Deeks J.J. Paradis V. Bedossa P. Newsome P.N. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019 156 6 1717 1730 10.1053/j.gastro.2019.01.042 30689971
    [Google Scholar]
  30. Tada T. Kumada T. Toyoda H. Nakamura S. Shibata Y. Yasuda S. Watanuki Y. Tsujii K. Fukuda N. Fujioka M. Takeshima K. Niwa F. Ogawa S. Hashinokuchi S. Kataoka S. Ichikawa H. Iijima H. Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction. Hepatol. Res. 2020 50 12 1319 1327 10.1111/hepr.13563 32876367
    [Google Scholar]
  31. Yoo J. Lee J.M. Joo I. Lee D.H. Yoon J.H. Kang H.J. Ahn S.J. Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis. Ultrasonography 2020 39 2 121 129 10.14366/usg.19034 31693842
    [Google Scholar]
  32. Bao J. Lv Y. Wang K. Wang Q. Chen Y. Dong Y. Zhu Y. Wang W. A comparative study of ultrasound attenuation imaging, controlled attenuation parameters, and magnetic resonance spectroscopy for the detection of hepatic steatosis. J. Ultrasound Med. 2023 42 7 1481 1489 10.1002/jum.16158 36583414
    [Google Scholar]
  33. Honda Y. Yoneda M. Imajo K. Nakajima A. Elastography techniques for the assessment of liver fibrosis in non-alcoholic fatty liver disease. Int. J. Mol. Sci. 2020 21 11 4039 10.3390/ijms21114039 32516937
    [Google Scholar]
  34. McPherson S. Armstrong M.J. Cobbold J.F. Corless L. Anstee Q.M. Aspinall R.J. Barclay S.T. Brennan P.N. Cacciottolo T.M. Goldin R.D. Hallsworth K. Hebditch V. Jack K. Jarvis H. Johnson J. Li W. Mansour D. McCallum M. Mukhopadhya A. Parker R. Ross V. Rowe I.A. Srivastava A. Thiagarajan P. Thompson A.I. Tomlinson J. Tsochatzis E.A. Yeoman A. Alazawi W. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): Consensus recommendations from the British association for the study of the liver and british society of gastroenterology NAFLD special interest group. Lancet Gastroenterol. Hepatol. 2022 7 8 755 769 10.1016/S2468‑1253(22)00061‑9 35490698
    [Google Scholar]
  35. Stefan N. Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022 10 4 284 296 10.1016/S2213‑8587(22)00003‑1 35183303
    [Google Scholar]
/content/journals/cmir/10.2174/0115734056335310250217064323
Loading
Correlation between Liver fat Content Determined by Ultrasonic Attenuation Imaging and Lipid Metabolism in Patients with Non-Alcoholic Fatty Liver Disease
Bentham Science Publishers , e15734056335310; https://doi.org/10.2174/0115734056335310250217064323
/content/journals/cmir/10.2174/0115734056335310250217064323
/content/journals/cmir/10.2174/0115734056335310250217064323
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: Type 2 diabetes ; Non-alcoholic fatty liver disease ; Attenuation imaging

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test